Dr. John Cush RheumNow
6 years ago
Pfizer announced the FDA has approved tofacitinib (Xeljanz) in children (>2yrs) w/ polyarticular JIA. Approval based on a 225 pt, Phase 3, 18 wk Open Run-in followed by 26-wk randomized, withdrawal study of placebo vs tofa 5 mg qd (or wt based oral soln) https://t.co/9Xo3lriINH
Dr. John Cush RheumNow
6 years ago
Study of early axSpA from the DESIR cohort looked at MRIs of the SI joint/spine @baseline, 2 & 5 yrs; showed that bone marrow edema pn MRI‐SIJ and ‐spine at baseline predicted of ‐year damage pm MRI‐SIJ [OR=4.2] and MRI‐spine [OR=10.7] https://t.co/3PAJ5Zt4Pp
Dr. John Cush RheumNow
6 years ago
Among a 112 patient inflammatory myositis cohort, inclusion body myositis was rare (4 pts) - they tend to be older (67 yrs), male predominance, lower CK (1326-1968), less severe weakness 3.75/5) and poor response to immunosuppressives. https://t.co/VxLOAjstWo
On Friday, Gilead and Galapagos announced that the European Commission (EC) has granted marketing authorization for filgotinib (trade name, Jyseleca) their oral, once-daily, JAK1 inhibitor for the treatment of adults with moderate to severe active rheumatoid arthritis (RA) who have responded inadequately to, or are intolerant to, one or more disease modifying anti-rheumatic drugs (DMARDs).
Lancet reports that in a randomized, blinded, controlled trial, gabapentin failed to significantly lower pain scores in women with chronic pelvic pain, and was associated with higher adverse event rates compared to placebo.
Dr. John Cush RheumNow
6 years ago
The RheumNow Podcast is up! Cardiovascular Risk in Psoriatic Disease, Higher COVID rates in young adults, Reimbursements for Rheumatologists and more. Watch here>> https://t.co/cBHTeUQhff or liste to podcast here> https://t.co/KBgmsoGRzU or on iTunes> https://t.co/FHJv01AAbC
Dr. John Cush RheumNow
6 years ago
Nice overview of what our colleagues are upto at the gout education society - Drs. Jas Singh, Hyun Choi and Tuhina Neogi!! https://t.co/9v2m0EcvhT https://t.co/3iYv0WlcL9
Dr. John Cush RheumNow
6 years ago
High-risk coronary plaques (LRNC) assessed by Coronary CT scores in 209 biologic naive Psoriasis pts. LNRC correlated w/ Framingham risk & Dz activity. After 1 year those on biologics had signif reduction in LRNC, but those not on biologics had no change https://t.co/8o74pjIs5n
Dr. Jack Cush reviews the news and Journal articles from the past week on RheumNow.com.
Dr. John Cush RheumNow
6 years ago
Rheums Win Big in 2021! According to the estimates from the Centers for Medicare & Medicaid Services (CMS), endocrinologists and rheumatologists are the big winners, at 17% and 16% projected increases, respectively https://t.co/I6etQZnFlv
Dr. John Cush RheumNow
6 years ago
Swedish GWAS study of >850,000 individuals shows Genetically predicted BMI (obesity) significantly increases RA riskk, but no correlation of RA risk to waist-to-hip ratios. https://t.co/YkzwjPOVyE
In June 2020, we failed to report on the ARD publication updating the 2019 update the European League Against Rheumatism (EULAR) recommendations for the pharmacological treatment of psoriatic arthritis (PsA) - these are presented below.
A phase II study of patients with early diffuse systemic sclerosis (SSc) has demonstrated improvement in SSc skin outcomes by targeting T cells and fibrosis with the bispecific monoclonal antibody romilkimab (RMK).
Romilkimab is an engineered, humanised, bispecific immunoglobulin-G4 antibody that binds and neutralises IL-4/IL-13 making it ideal for exploration in fibrosis.
Dr. John Cush RheumNow
6 years ago
FDA has issued a new guidance document outlining the inclusion of geriatric information in drug labeling detect; especially noting geriatic studies and when efficacy and safety differs from that seen in younger adults https://t.co/jTLDae3Gff
